Scribe Therapeutics Inc.

NASDAQ: SCTX · Healthcare · Biotechnology

PublicHQ Alameda, CA · AlamedaReports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 46

v0.1 · 5/100 weight · pillars only

↑ market scale, workforce scale · ↓ listing tenure, workforce scale

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

as of 2026-09-01

Market cap

$494.2M

as of 2026-09-01

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Scribe Therapeutics Inc.’s financial profile?

Scribe Therapeutics Inc. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

Eikon Therapeutics, Inc. Common Stock——Tectonic Therapeutic, Inc.——Zura Bio Limited——Vogenx Inc.——MapLight Therapeutics, Inc.——Cabaletta Bio, Inc.——

Neighbors

Alameda →

Lam Research Corporation$18.4B——Ross Stores, Inc.$22.8B78B+Workday, Inc.$9.6B80B+Block, Inc.$24.2B69B Veeva Systems Inc.$3.2B81B+PG&E Corporation$24.9B69B

Key facts

CEOBenjamin L. Oakes

SectorHealthcare

IndustryBiotechnology

HeadquartersAlameda, CA

ExchangeNASDAQ: SCTX

Employees89

IPO date2026-07-24

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.